Ostatní
Návod 
Biogen Inc.
BIIB
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
22.8B
Obrat
10B
Zisk
1B
Aktiva
29B
Dluh
7B
ROE
0%
ROA
0%
PE
21
PS
3
Cena 1R
110-190
⌀ Cena
143.31
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
11-02-2026
Poslední dividenda
Profil
Společnost Biogen Inc. objevuje, vyvíjí, vyrábí a dodává terapie pro léčbu neurologických a neurodegenerativních onemocnění. Společnost nabízí TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI a FAMPYRA pro roztroušenou sklerózu (RS); SPINRAZA pro spinální svalovou atrofii; a FUMADERM pro léčbu ložiskové psoriázy. Dále obsahuje BENEPALI, etanerceptový biosimilar odkazující na ENBREL; ADUHELM pro léčbu Alzheimerovy choroby; IMRALDI, adalimumabový biosimilar odkazující na HUMIRA; a FLIXABI, infliximabový biosimilar odkazující na REMICADE. Společnost dále nabízí přípravek RITUXAN k léčbě nehodgkinských lymfomů, chronické lymfatické leukémie (CLL), revmatoidní artritidy, dvou forem vaskulitidy spojené s ANCA a pemphigus vulgaris; RITUXAN HYCELA pro nehodgkinské lymfomy a CLL; přípravek GAZYVA k léčbě CLL a folikulárního lymfomu; a přípravek OCREVUS k léčbě relabující RS a primárně progresivní RS; a další antiCD20 terapie. Dále vyvíjí BIIB135, BIIB061, BIIB091 a BIIB107 pro RS a neuroimunologii; Aducanumab, Lecanemab, BIIB076 a BIIB080 pro léčbu Alzheimerovy choroby a demence; BIIB067, BIIB078, BIIB105, BIIB100 a BIIB110 pro léčbu neuromuskulárních poruch; BIIB124, BIIB094, BIIB118, BIIB101 a BIIB122 pro léčbu Parkinsonovy choroby a pohybových poruch; BIIB125 a BIIB104 pro léčbu neuropsychiatrie; Dapirolizumab pegol a BIIB059 pro léčbu nemocí souvisejících s imunologií; BIIB093 a BIIB131 pro léčbu akutní neurologie; a BYBYROKRATICKÉ BOLESTI; Biosimilary OOVIZ, BIIB074 BIIB800 a SB15, které jsou v různých fázích vývoje. Společnost má spolupráci a licenční smlouvy s Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; a Sage Therapeutics, Inc. Biogen Inc. byla založena v roce 1978 a má sídlo v Cambridge, Massachusetts.
Sektor
Healthcare
Odvětví
Drug Manufacturers - General
Počet zaměstnanců
7605
Založení
1991-09-17
Podobné společnosti
$ 104.50
- $ 1.48
$ 253.84
+ $ 1.12
$ 29.05
+ $ 0.39
$ 450.61
+ $ 1.70
$ 24.30
+ $ 0.33
$ 54.68
- $ 0.32
$ 261.57
- $ 2.21
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 9,810.6 | 9,810.6 | 9,675.9 | 9,835.6 | 10,173.4 | 10,981.7 | 13,444.6 | 14,377.9 | 13,452.9 | 12,273.9 | 11,448.8 | 10,763.8 | 9,703.3 | 6,932.2 | 5,516.5 | 5,048.6 | 4,716.4 | |
| Cost of Revenues | 2,897.0 | 2,897.0 | 2,310.4 | 2,533.4 | 2,278.3 | 2,109.7 | 1,805.2 | 1,955.4 | 1,816.3 | 1,630.0 | 1,478.7 | 1,240.4 | 1,171.0 | 857.7 | 545.5 | 466.8 | 400.3 | |
| Gross Profit | 6,913.6 | 6,913.6 | 7,365.5 | 7,302.2 | 7,895.1 | 8,872.0 | 11,639.4 | 12,422.5 | 11,636.6 | 10,643.9 | 9,970.1 | 9,523.4 | 8,532.3 | 6,074.5 | 4,971.0 | 4,581.9 | 4,316.2 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 2,279.3 | 2,454.8 | 2,645.5 | 2,431.0 | 2,454.7 | 2,465.8 | 2,464.9 | 2,290.5 | 2,386.3 | 2,530.3 | |
| Cost of Revenues | 496.3 | 876.6 | 946.2 | 577.9 | 583.5 | 638.7 | 955.8 | 498.1 | 618.3 | 659.6 | |
| Gross Profit | 1,783.0 | 1,578.2 | 1,699.3 | 1,853.1 | 1,871.2 | 1,827.1 | 1,509.1 | 1,792.4 | 1,768.0 | 1,870.7 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 2,462.0 | 2,231.1 | 2,501.2 | 3,990.9 | 2,280.6 | 2,597.2 | 2,253.6 | 1,973.3 | 2,012.8 | 1,893.4 | 1,444.1 | 1,334.9 | 1,219.6 | 1,248.6 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 2,549.7 | 2,403.6 | 2,674.3 | 2,504.5 | 2,374.7 | 2,106.3 | 1,935.5 | 1,947.9 | 2,113.1 | 2,232.3 | 1,712.1 | 1,277.5 | 1,373.9 | 1,289.6 | |
| Depreciation & Amortization | 935.4 | 935.4 | 673.2 | 494.8 | 365.9 | 815.9 | 257.2 | 476.1 | 747.3 | 814.7 | 385.6 | 382.6 | 489.8 | 342.9 | 202.2 | 208.6 | 354.1 | |
| Total Operating Expenses | 5,036.1 | 5,036.1 | 4,875.2 | 6,005.4 | 4,993.2 | 6,064.0 | 7,193.1 | 5,386.8 | 5,635.8 | 5,116.1 | 4,317.0 | 4,508.5 | 4,615.5 | 3,584.4 | 3,132.5 | 2,838.1 | 2,747.1 | |
| Operating Income | 1,877.5 | 1,877.5 | 2,490.3 | 2,097.3 | 2,320.2 | 2,840.7 | 4,550.1 | 7,042.6 | 5,888.6 | 5,344.2 | 5,150.4 | 4,891.0 | 3,972.4 | 2,515.5 | 1,855.8 | 1,724.7 | 1,248.9 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 570.9 | 736.3 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 608.5 | 788.2 | ||
| Depreciation & Amortization | 355.7 | 202.2 | 194.3 | 183.2 | 184.0 | 182.8 | 158.9 | 147.5 | 140.1 | 125.0 | ||
| Total Operating Expenses | 1,840.0 | 964.4 | 1,111.2 | 1,120.5 | 1,362.2 | 1,249.9 | 1,142.6 | 1,102.0 | 1,310.3 | 1,635.9 | ||
| Operating Income | -57.0 | 613.8 | 588.1 | 732.6 | 509.0 | 577.2 | 366.5 | 690.4 | 291.6 | -141.2 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 125.0 | 87.8 | 67.6 | 276.5 | 89.3 | 11.0 | 42.0 | 120.0 | 112.5 | 78.5 | 63.4 | 22.1 | 12.2 | 8.2 | 29.5 | 19.2 | 22.3 | |
| Interest Expense | 267.5 | 246.0 | 250.3 | 246.9 | 246.6 | 253.6 | 222.5 | 187.4 | 200.6 | 250.8 | 260.0 | 95.5 | 29.5 | 31.9 | 36.5 | 33.0 | 36.1 | |
| Other Expense | -476.0 | -476.0 | -584.3 | -800.5 | 1,271.6 | -1,095.5 | 497.4 | 83.3 | -101.2 | -399.0 | -720.1 | -247.6 | 29.9 | -9.5 | 16.6 | -32.5 | -325.3 | |
| IBT | 1,401.5 | 1,401.5 | 1,906.0 | 1,296.8 | 3,591.8 | 1,745.2 | 5,047.5 | 7,125.9 | 5,899.6 | 5,128.8 | 4,933.0 | 4,767.3 | 3,946.6 | 2,480.6 | 1,855.1 | 1,711.2 | 1,229.9 | |
| Income Tax Expense | 108.1 | 108.1 | 273.8 | 135.3 | 632.8 | 52.5 | 992.3 | 1,158.0 | 1,425.6 | 2,458.7 | 1,237.3 | 1,161.6 | 989.9 | 601.0 | 470.6 | 444.5 | 331.3 | |
| Net Income | 1,293.4 | 1,293.4 | 1,632.2 | 1,161.1 | 3,046.9 | 1,556.1 | 4,000.6 | 5,888.5 | 4,430.7 | 2,539.1 | 3,702.8 | 3,547.0 | 2,934.8 | 1,862.3 | 1,380.0 | 1,234.4 | 1,005.3 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 37.2 | 31.6 | 32.3 | 23.9 | 18.5 | 11.6 | 20.1 | 17.4 | 23.8 | 95.9 | ||
| Interest Expense | 67.5 | 67.4 | 72.6 | 60.0 | 60.0 | 59.8 | 61.3 | 69.2 | 71.5 | 63.8 | ||
| Other Expense | -154.0 | -56.5 | 155.9 | -421.4 | -217.5 | -126.2 | 332.2 | -225.6 | -133.6 | -376.0 | ||
| IBT | -211.0 | 557.3 | 744.0 | 311.2 | 291.5 | 451.0 | 698.7 | 464.8 | 291.6 | -141.2 | ||
| Income Tax Expense | -162.6 | 90.8 | 109.2 | 70.7 | 24.8 | 62.5 | 115.1 | 71.4 | 42.7 | -72.9 | ||
| Net Income | -48.4 | 466.5 | 634.8 | 240.5 | 266.7 | 388.5 | 583.6 | 393.4 | 249.7 | -68.1 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $8.02 | $20.96 | $10.44 | $24.86 | $31.47 | $21.62 | $11.94 | $16.96 | $15.38 | $12.42 | $7.86 | $5.80 | $5.09 | $3.98 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 | $15.34 | $12.37 | $7.81 | $5.76 | $5.04 | $3.94 | |
| Shares Outstanding | 146.7 | 146.7 | 145.7 | 144.7 | 145.3 | 149.1 | 160.9 | 187.1 | 204.9 | 212.6 | 218.4 | 230.7 | 236.4 | 236.9 | 237.9 | 242.4 | 252.3 | |
| Diluted Shares Outstanding | 146.7 | 146.7 | 145.9 | 145.6 | 146.0 | 149.6 | 161.3 | 187.4 | 205.3 | 213.0 | 218.8 | 231.2 | 237.2 | 238.3 | 239.7 | 245.0 | 254.9 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.72 | $-0.47 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.71 | $-0.47 | ||
| Shares Outstanding | 146.7 | 146.6 | 145.9 | 145.9 | 145.7 | 145.7 | 145.6 | 145.2 | 144.9 | 144.8 | ||
| Diluted Shares Outstanding | 146.7 | 147.1 | 145.9 | 145.9 | 146.1 | 145.9 | 145.9 | 145.9 | 145.7 | 144.8 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 1,908.9 | 2,375.0 | 1,049.9 | 3,419.3 | 2,261.4 | 1,331.2 | 2,913.7 | 1,224.6 | 1,573.8 | 2,326.5 | 1,308.0 | 1,204.9 | 602.6 | 570.7 | 514.5 | 759.6 | |
| Short Term Investments | 0.0 | 0.0 | 0.0 | 1,473.5 | 1,541.1 | 1,278.9 | 1,562.2 | 2,313.4 | 2,115.2 | 2,568.6 | 2,120.5 | 640.5 | 620.2 | 1,135.0 | 1,176.1 | 448.1 | |
| Total Cash & ST Investments | 1,908.9 | 2,375.0 | 1,049.9 | 4,892.8 | 3,802.5 | 2,610.1 | 4,475.9 | 3,538.0 | 3,689.0 | 4,895.1 | 3,428.5 | 1,845.4 | 1,222.7 | 1,705.7 | 1,690.7 | 1,207.7 | |
| Accounts Receivable | 2,078.2 | 1,868.8 | 2,100.0 | 2,136.4 | 1,549.4 | 1,913.8 | 1,880.5 | 1,958.5 | 1,787.0 | 1,441.6 | 1,227.0 | 1,292.4 | 824.4 | 686.8 | 584.6 | 840.0 | |
| Inventory | 2,506.1 | 2,460.5 | 2,527.4 | 1,344.4 | 1,351.5 | 1,068.6 | 804.2 | 929.9 | 902.7 | 1,001.6 | 893.4 | 804.0 | 659.0 | 447.4 | 326.8 | 289.1 | |
| Other Current Assets | 615.3 | 752.5 | 1,182.0 | 1,417.6 | 1,153.1 | 1,294.6 | 1,221.2 | 1,214.5 | 1,494.6 | 1,393.9 | 1,151.4 | 730.8 | 478.8 | 404.4 | 2,064.0 | 22.1 | |
| Total Current Assets | 7,108.5 | 7,456.8 | 6,859.3 | 9,791.2 | 7,856.5 | 6,887.1 | 8,381.8 | 7,640.9 | 7,873.3 | 8,732.2 | 6,700.3 | 4,672.7 | 3,184.9 | 3,244.3 | 2,975.4 | 2,540.4 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 3,862.8 | 2,758.8 | 2,598.3 | 2,375.0 | 1,699.2 | 1,908.9 | 1,074.4 | 1,049.9 | 2,287.9 | 2,617.8 | |
| Short Term Investments | 97.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3,460.5 | |
| Total Cash & ST Investments | 3,960.4 | 2,758.8 | 2,598.3 | 2,375.0 | 1,699.2 | 1,908.9 | 1,074.4 | 1,049.9 | 2,287.9 | 6,078.3 | |
| Accounts Receivable | 1,850.0 | 2,084.0 | 1,996.5 | 1,868.8 | 1,988.1 | 2,078.2 | 1,999.7 | 2,100.0 | 2,209.7 | 2,124.0 | |
| Inventory | 2,209.4 | 2,274.3 | 2,273.9 | 2,460.5 | 2,469.2 | 2,506.1 | 2,516.8 | 2,527.4 | 2,982.4 | 1,333.5 | |
| Other Current Assets | 916.8 | 850.6 | 757.3 | 752.5 | 674.0 | 615.3 | 1,165.3 | 1,182.0 | 974.1 | 895.9 | |
| Total Current Assets | 8,936.6 | 7,967.7 | 7,626.0 | 7,456.8 | 6,830.5 | 7,108.5 | 6,756.2 | 6,859.3 | 8,454.1 | 10,431.7 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 3,638.7 | 3,537.7 | 3,729.7 | 3,702.5 | 3,791.8 | 3,844.8 | 3,674.3 | 3,601.2 | 3,182.4 | 2,501.8 | 2,187.6 | 1,765.7 | 1,750.7 | 1,742.2 | 1,571.4 | 1,641.6 | |
| Goodwill | 6,227.4 | 6,478.9 | 6,219.2 | 5,749.0 | 5,761.1 | 5,762.1 | 5,757.8 | 5,706.4 | 4,632.5 | 3,669.3 | 2,663.8 | 1,760.2 | 1,232.9 | 1,201.3 | 1,146.3 | 1,146.3 | |
| Intangible Assets | 8,232.9 | 9,691.2 | 8,363.0 | 1,850.1 | 2,221.3 | 3,084.3 | 3,527.4 | 3,120.0 | 3,879.6 | 3,808.3 | 4,085.1 | 4,028.5 | 4,474.7 | 1,631.5 | 1,608.2 | 1,772.8 | |
| Long-Term Investments | 354.1 | 226.7 | 460.7 | 2,234.9 | 2,831.5 | 5,040.6 | 5,893.0 | 5,220.4 | 4,084.8 | 4,165.2 | 3,868.0 | 2,089.4 | 1,220.1 | 2,310.7 | 1,748.3 | 991.3 | |
| Other Long-Term Assets | 327.4 | 333.8 | 284.3 | 0.0 | 0.0 | -1,369.5 | -3,232.1 | -2,153.9 | 3,057.3 | 2,829.4 | 2,760.4 | 1,470,652.0 | 625,772.0 | 2,036,658.0 | 1,416,737.0 | 743,101.0 | |
| Total Long-Term Assets | 19,695.6 | 20,592.5 | 19,985.5 | 14,762.9 | 16,020.8 | 17,731.8 | 18,852.5 | 17,648.0 | 15,779.3 | 14,144.6 | 12,804.5 | 9,643.9 | 8,678.4 | 6,885.8 | 6,074.2 | 5,552.1 | |
| Total Assets | 26,804.1 | 28,049.3 | 26,844.8 | 24,554.1 | 23,877.3 | 24,618.9 | 27,234.3 | 25,288.9 | 23,652.6 | 22,876.8 | 19,504.8 | 14,316.6 | 11,863.3 | 10,130.1 | 9,049.6 | 8,092.5 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 3,406.2 | 3,433.3 | 3,478.8 | 3,537.7 | 3,591.3 | 3,638.7 | 3,703.4 | 3,729.7 | 3,762.5 | 3,673.7 | |
| Goodwill | 6,490.7 | 6,493.1 | 6,477.1 | 6,478.9 | 6,485.8 | 6,227.4 | 6,227.4 | 6,219.2 | 6,807.5 | 5,753.7 | |
| Intangible Assets | 9,331.9 | 9,467.5 | 9,584.6 | 9,691.2 | 9,805.5 | 8,232.9 | 8,284.7 | 8,363.0 | 7,344.6 | 1,776.4 | |
| Long-Term Investments | 729.7 | 224.0 | 186.0 | 226.7 | 353.3 | 354.1 | 382.0 | 460.7 | 754.7 | 2,312.9 | |
| Other Long-Term Assets | 0.0 | 413.7 | 373.1 | 333.8 | 278.1 | 327.4 | 315.6 | 284.3 | 0.0 | 0.0 | |
| Total Long-Term Assets | 20,270.9 | 20,362.5 | 20,407.1 | 20,592.5 | 21,482.7 | 19,695.6 | 19,811.4 | 19,985.5 | 19,739.1 | 14,725.1 | |
| Total Assets | 29,207.5 | 28,330.2 | 28,033.1 | 28,049.3 | 28,313.2 | 26,804.1 | 26,567.6 | 26,844.8 | 28,193.2 | 25,156.8 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 354.5 | 424.2 | 403.3 | 491.5 | 589.2 | 454.9 | 530.8 | 370.5 | 395.5 | 279.8 | 267.4 | 229.2 | 219.9 | 204.0 | 186.4 | 162.5 | |
| Short-Term Debt | 193.0 | 1,748.6 | 240.3 | 0.0 | 999.1 | 0.0 | 1,495.8 | 0.0 | 3.2 | 4.7 | 4.8 | 3.1 | 3.5 | 453.4 | 3.3 | 137.2 | |
| Other Current Liabilities | 2,279.1 | 2,807.7 | 2,530.3 | 2,781.3 | 3,299.1 | 3,287.3 | 3,368.0 | 2,924.7 | 2,901.3 | 2,903.5 | 2,249.8 | 1,866.5 | 1,362.2 | 852.0 | 909.6 | 709.1 | |
| Current Liabilities | 3,108.2 | 5,528.8 | 3,434.3 | 3,272.8 | 4,298.2 | 3,742.2 | 4,863.8 | 3,295.2 | 3,368.2 | 3,336.9 | 2,577.7 | 2,219.7 | 1,758.3 | 1,657.4 | 912.9 | 1,050.1 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 413.1 | 408.4 | 391.5 | 424.2 | 422.7 | 354.5 | 387.0 | 403.3 | 440.1 | 445.4 | |
| Short-Term Debt | 0.0 | 0.0 | 1,749.1 | 1,748.6 | 1,748.1 | 0.0 | 250.0 | 240.3 | 500.0 | 0.0 | |
| Other Current Liabilities | 2,773.6 | 2,660.5 | 2,530.7 | 2,807.7 | 2,755.1 | 2,472.1 | 2,354.6 | 2,533.3 | 3,838.4 | 2,481.1 | |
| Current Liabilities | 3,290.0 | 3,183.7 | 5,297.4 | 5,528.8 | 5,425.0 | 3,108.2 | 3,222.8 | 3,434.3 | 5,022.3 | 3,186.5 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 6,292.0 | 4,881.7 | 7,188.2 | 6,614.0 | 6,604.4 | 7,828.2 | 4,871.7 | 5,936.5 | 5,935.0 | 6,512.7 | 6,521.5 | 582.1 | 592.4 | 687.4 | 1,060.8 | 1,066.4 | |
| Capital Leases | 367.5 | 334.5 | 400.0 | 333.0 | 330.4 | 402.0 | 412.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 590.6 | 190.5 | 641.8 | 334.7 | 694.5 | 1,032.8 | 2,810.8 | 1,636.2 | 122.6 | 93.1 | 124.9 | 50.7 | 232.6 | 217.3 | 248.6 | 201.0 | |
| Total Liabilities | 10,915.0 | 11,333.3 | 12,045.4 | 11,165.7 | 12,917.6 | 13,932.8 | 13,895.2 | 12,257.3 | 11,054.5 | 10,748.2 | 10,129.9 | 3,502.5 | 3,242.5 | 3,166.3 | 2,622.6 | 2,643.1 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 6,590.1 | 6,594.6 | 4,872.1 | 4,881.7 | 4,902.8 | 6,659.5 | 6,696.6 | 7,188.2 | 7,215.2 | 6,589.0 | |
| Capital Leases | 305.0 | 310.9 | 323.4 | 334.5 | 357.0 | 367.5 | 406.5 | 400.0 | 428.8 | 304.4 | |
| Def. Tax Liability | 358.1 | 118.3 | 133.2 | 190.5 | 882.4 | 590.6 | 658.1 | 641.8 | 728.1 | 143.9 | |
| Total Liabilities | 11,000.0 | 10,696.2 | 11,054.4 | 11,333.3 | 11,954.3 | 10,915.0 | 11,354.6 | 12,045.4 | 13,713.5 | 10,696.3 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Retained Earnings | 18,604.6 | 19,259.8 | 17,627.6 | 16,466.5 | 13,911.7 | 13,976.3 | 16,455.4 | 16,257.0 | 15,810.4 | 15,071.6 | 12,208.4 | 9,283.9 | 6,349.1 | 4,486.8 | 3,106.8 | 1,872.5 | |
| Comprehensive Income | -146.0 | -136.2 | -153.7 | -164.9 | -106.7 | -299.0 | -135.2 | -240.4 | -318.4 | -319.9 | -224.0 | -59.5 | -27.7 | -55.3 | -26.5 | -21.6 | |
| Total Common Equity | 15,889.1 | 16,716.0 | 14,799.4 | 13,388.4 | 10,959.7 | 10,686.1 | 13,339.1 | 13,031.6 | 12,598.1 | 12,128.6 | 9,374.9 | 10,814.0 | 8,620.8 | 6,963.8 | 6,427.0 | 5,396.5 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Retained Earnings | 20,601.6 | 20,135.1 | 19,500.3 | 19,259.8 | 18,993.1 | 18,604.6 | 18,021.0 | 17,627.6 | 17,377.9 | 17,446.0 | |
| Comprehensive Income | -214.8 | -238.1 | -174.5 | -136.2 | -145.7 | -146.0 | -160.5 | -153.7 | -159.3 | -172.8 | |
| Total Common Equity | 18,207.5 | 17,634.0 | 16,978.7 | 16,716.0 | 16,358.9 | 15,889.1 | 15,213.0 | 14,799.4 | 14,479.7 | 14,460.5 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 6,852.5 | 6,630.3 | 7,338.2 | 6,614.0 | 7,603.5 | 7,828.2 | 6,367.5 | 5,936.5 | 5,935.0 | 6,512.7 | 6,521.5 | 585.2 | 595.9 | 1,140.8 | 1,064.1 | 1,203.5 | |
| Book Value | 15,889.1 | 16,716.0 | 14,799.4 | 13,388.4 | 10,959.7 | 10,686.1 | 13,339.1 | 13,031.6 | 12,598.1 | 12,128.6 | 9,374.9 | 10,814.0 | 8,620.8 | 6,963.8 | 6,427.0 | 5,449.4 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.1 | -6.4 | |
| Book Value | 18,207.5 | 17,634.0 | 16,978.7 | 16,716.0 | 16,358.9 | 15,889.1 | 15,213.0 | 14,799.4 | 14,479.7 | 14,460.5 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1,157.6 | 1,292.9 | 1,632.2 | 1,161.5 | 2,961.6 | 1,727.6 | 4,060.5 | 5,888.5 | 4,474.0 | 2,670.1 | 3,695.7 | 3,593.2 | 2,941.6 | 1,862.3 | 1,380.0 | 1,266.7 | 898.6 | |
| Depreciation & Amortization | 571.5 | 779.9 | 673.2 | 494.8 | 518.4 | 487.7 | 457.2 | 680.6 | 1,016.6 | 1,081.0 | 682.7 | 600.4 | 688.2 | 531.7 | 365.6 | 358.9 | 354.1 | |
| Stock-Based Compensation | 260.5 | 290.8 | 291.2 | 264.2 | 254.1 | 238.6 | 198.3 | 182.3 | 157.5 | 128.0 | 154.8 | 161.4 | 155.3 | 136.3 | 118.6 | 113.0 | 167.8 | |
| Change Working Capital | -751.0 | -1,057.6 | -155.2 | -648.7 | -890.3 | -145.5 | -187.2 | 199.3 | 400.2 | 235.4 | 73.0 | -575.5 | -484.4 | 87.4 | 103.7 | -184.6 | 3.6 | |
| Change In Accounts Receivable | 36.7 | 42.1 | 194.2 | 0.0 | -203.4 | 324.8 | 2.8 | 68.8 | -205.2 | -435.6 | -241.4 | 29.0 | -512.4 | -126.8 | 3.6 | -73.4 | -99.2 | |
| Change In Accounts Payable | -72.4 | 0.0 | 0.0 | 0.0 | 0.0 | -94.2 | 330.9 | 133.6 | 335.8 | -538.4 | 712.6 | -523.7 | 149.9 | 123.9 | 206.4 | 27.5 | 102.2 | |
| Change In Inventories | -254.0 | -64.7 | -273.8 | 0.0 | -320.2 | -462.4 | -316.3 | -19.2 | -52.1 | -94.5 | -165.6 | -174.4 | -185.9 | -244.0 | -140.3 | -59.2 | -4.5 | |
| Other Non-cash Items | 1,674.5 | 537.0 | 592.2 | 581.2 | -1,290.9 | 1,758.3 | -448.0 | 60.8 | 31.1 | 344.8 | 91.2 | 82.2 | -50.3 | -27.6 | 28.8 | 20.2 | 282.0 | |
| Cash from Operations | 1,783.9 | 0.0 | 0.0 | 1,547.2 | 1,384.3 | 3,639.9 | 4,229.8 | 7,078.6 | 6,187.7 | 4,551.0 | 4,522.4 | 3,716.1 | 2,942.1 | 2,345.1 | 1,879.9 | 1,727.7 | 1,624.7 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -48.9 | 466.5 | 634.8 | 240.5 | 266.7 | 388.5 | 583.6 | 393.4 | 248.9 | -68.3 | |
| Depreciation & Amortization | 200.2 | 202.2 | 194.3 | 183.2 | 184.0 | 182.8 | 158.9 | 147.5 | 140.1 | 125.0 | |
| Stock-Based Compensation | 0.0 | 75.3 | 74.9 | 81.0 | 75.1 | 72.7 | 70.6 | 72.8 | 54.9 | 62.2 | |
| Change Working Capital | -108.7 | 174.2 | -789.6 | -333.5 | 28.3 | 233.8 | -188.6 | -228.7 | -648.1 | 314.4 | |
| Change In Accounts Receivable | -21.0 | 229.4 | -55.7 | -110.6 | 82.5 | 114.5 | -87.2 | 84.4 | 137.8 | -98.3 | |
| Change In Accounts Payable | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -503.2 | 430.8 | |
| Change In Inventories | -29.4 | -7.4 | -89.9 | 62.0 | -66.4 | -19.2 | -110.5 | -77.7 | -96.0 | 30.2 | |
| Other Non-cash Items | 302.4 | 100.5 | 77.8 | 115.9 | 265.2 | 110.4 | 88.3 | 128.3 | 144.8 | 365.9 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.5 | 592.4 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -316.3 | -153.8 | -359.8 | 277.0 | -243.2 | -294.9 | -551.8 | -669.5 | -886.1 | -1,962.8 | -727.7 | -643.0 | -287.8 | -3,509.0 | -261.2 | -252.2 | -173.1 | |
| Acquisitions | -6,926.1 | 0.0 | -1,074.8 | -6,138.0 | 990.3 | 28.1 | -565.5 | -120.7 | -2,176.6 | -1,200.0 | -1,200.0 | -1,048.8 | -375.0 | -15.0 | -72.4 | -5.0 | -157.4 | |
| Investments | -1,020.4 | -1,258.3 | 0.0 | -5,140.7 | -3,448.5 | -3,808.7 | -6,838.7 | -5,252.6 | -8,157.7 | -5,355.2 | -7,913.2 | -6,864.9 | -3,583.2 | -3,278.1 | -3,334.4 | -3,713.3 | -1,992.9 | |
| Sales of Investment | 6,282.3 | 79.7 | 551.5 | 7,500.4 | 3,671.0 | 3,498.9 | 7,374.3 | 6,486.3 | 9,173.7 | 5,565.9 | 7,378.9 | 4,063.0 | 2,718.9 | 5,190.1 | 2,759.6 | 2,318.0 | 2,668.7 | |
| Other Investing Activities | -13.5 | 0.0 | 0.0 | -599.7 | 607.0 | 12.9 | -26.9 | 27.0 | 0.4 | -11.0 | -22.8 | -59.9 | -16.0 | 7.4 | -41.9 | 2.2 | 0.0 | |
| Cash from Investing | -1,994.0 | 0.0 | 0.0 | -4,101.0 | 1,576.6 | -563.7 | -608.6 | 470.5 | -2,046.3 | -2,963.1 | -2,484.8 | -4,553.6 | -1,543.0 | -1,604.7 | -950.3 | -1,650.3 | 345.3 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | 43.9 | -51.5 | -26.6 | -47.1 | -66.3 | -130.0 | -42.6 | -120.9 | -65.2 | -87.6 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1,074.8 | 0.0 | 0.0 | -590.5 | -6,335.6 | |
| Investments | 0.0 | -91.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1,020.4 | |
| Sales of Investment | 0.0 | 56.6 | 0.0 | 0.0 | -40.6 | 24.8 | 511.7 | 55.6 | 13.4 | 5,701.6 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -10.0 | -0.2 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -652.3 | -1,742.2 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -2,137.3 | 0.0 | 0.0 | 187.3 | -1,002.2 | -170.0 | -1,500.0 | 0.0 | -3.2 | -560.9 | -2.7 | -2.1 | -2.7 | -452.3 | -2.4 | -11.5 | -18.1 | |
| Debt Issued | 2,400.8 | 6,630.3 | -707.9 | 911.5 | 12.7 | -54.7 | 2,960.7 | 431.0 | 4.7 | -16.8 | -6.1 | 5,938.4 | -8.1 | -92.5 | 79.1 | -128.0 | 1,221.6 | |
| Issuance of Common Stock | -30.5 | 0.0 | 0.0 | -44.3 | -1.9 | -0.7 | -4.6 | 0.0 | -2.1 | -5.3 | 43.7 | 54.2 | 54,887.0 | 66,770.0 | 67,493.0 | 314.7 | 183.5 | |
| Repurchase of Common Stock | 9.3 | 0.0 | 0.0 | 0.0 | -750.0 | -1,800.0 | -6,679.1 | -5,868.3 | -4,352.6 | -1,365.4 | -1,000.0 | -5,000.0 | -886.8 | -400.3 | -984.7 | -498.0 | -2,077.6 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.7 | -4.6 | 0.0 | 0.0 | 0.0 | 0.0 | -5,930.5 | -54,832.1 | -66,703.2 | -67,425.5 | 0.0 | -11.8 | |
| Other Financing Activities | 10.9 | 0.0 | 0.0 | -38.0 | 6.8 | -114.8 | 2,915.6 | 7.9 | -114.1 | -448.4 | -28.8 | 11,864.8 | 78.7 | 69.4 | 42.2 | -125.1 | 139.0 | |
| Cash from Financing | -482.3 | 0.0 | 0.0 | 149.3 | -1,747.3 | -2,086.2 | -5,272.7 | -5,860.4 | -4,472.0 | -2,380.0 | -987.8 | 986.4 | -755.9 | -716.5 | -877.5 | -319.9 | -1,784.9 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -650.0 | 837.3 | |
| Debt Issued | 6,590.1 | -4.5 | -26.6 | -9.1 | -20.6 | -8.6 | -287.1 | -391.6 | 273.0 | 1,963.5 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.7 | 6.6 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 11.3 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -646.1 | 848.6 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -708.9 | 633.5 | 1,325.1 | -2,369.4 | 1,157.9 | 930.2 | -1,582.5 | 1,689.1 | -349.2 | -752.7 | 1,018.5 | 103.1 | 602.4 | 31.8 | 56.2 | -245.1 | 177.7 | |
| Closing Cash Balance | 1,908.9 | 3,008.5 | 2,375.0 | 1,049.9 | 3,419.3 | 2,261.4 | 1,331.2 | 2,913.7 | 1,224.6 | 1,573.8 | 2,326.5 | 1,308.0 | 1,204.9 | 602.6 | 570.7 | 514.5 | 759.6 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -856.6 | 1,104.0 | 160.5 | 223.3 | 675.8 | -209.7 | 834.5 | 24.5 | -1,238.0 | -329.9 | |
| Closing Cash Balance | 3,008.5 | 3,862.8 | 2,758.8 | 2,598.3 | 2,375.0 | 1,699.2 | 1,908.9 | 1,074.4 | 1,049.9 | 2,287.9 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1,467.6 | 2,050.8 | 2,515.7 | 1,235.8 | 1,141.1 | 3,345.0 | 3,678.0 | 6,409.1 | 5,301.6 | 2,588.2 | 3,794.7 | 3,073.1 | 2,654.4 | -1,163.9 | 1,618.7 | 1,475.6 | 1,451.6 | |
| Real Free Cash Flow | 1,207.1 | 1,760.0 | 2,224.5 | 971.6 | 887.0 | 3,106.4 | 3,479.7 | 6,226.8 | 5,144.1 | 2,460.2 | 3,639.9 | 2,911.7 | 2,499.1 | -1,300.2 | 1,500.1 | 1,362.6 | 1,283.8 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 555.9 | 1,226.3 | 144.3 | 212.2 | 694.6 | 805.6 | 583.2 | 432.3 | -52.7 | 504.8 | |
| Real Free Cash Flow | 555.9 | 1,151.0 | 69.4 | 131.2 | 619.5 | 732.9 | 512.6 | 359.5 | -107.6 | 442.6 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 20.6 | 21.2 | 86.1 |
| P/S | 2.7 | 5.3 | 578 |
| P/B | 1.5 | 4.4 | 582.9 |
| P/FCF | 14 | 17 | 10581.1 |
| Market cap | $22.8 | $33.1 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 20.7 % | 0 % |
| Debt to Income | 509.5 % | 210.9 % | 0 % |
| Debt to Free cash flow | 345.5 % | 72.6 % | 0 % |
| Interest expense percentage | 14.2 % | 5.7 % | 7 % |
| Current ratio | 2.7 | 2.3 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 7.1 % | 22.8 % | 0 % |
| ROA | 4.4 % | 13 % | 0 % |
| CapEx to Revenue | 0.8 % | 7.9 % | 10.5 % |
| RaD to Revenue | 0 % | 21.3 % | 0 % |
| ROEM | 1,290,019.7 | 1057174.5 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 70.5 % | 84.7 % | 77.7 % |
| Operating margin | 19.1 % | 34.3 % | 29.4 % |
| Net margin | 13.2 % | 25.5 % | 22.3 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 13 % | 0 % |
| Dividend payout percentage | 0 % | 399.5 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 146.7 mil | 197.9 mil |
| Employee count | 7.6 tis | 18.7 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
